poisar

Stocks · News reference

LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027

Jul 22, 2026, 12:02 PMBenzinga Newsdesk

LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LBRX
Source
benzinga
Observed
Jul 22, 2026, 12:02 PM
Checked
Jul 22, 2026, 12:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading